» Articles » PMID: 30728056

CircRNA Circ_0000190 Inhibits the Progression of Multiple Myeloma Through Modulating MiR-767-5p/MAPK4 Pathway

Overview
Publisher Biomed Central
Specialty Oncology
Date 2019 Feb 8
PMID 30728056
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Multiple myeloma (MM) accounts for 10% of all hematological malignancies. Dysregulation of microRNAs (miRNAs) or long non-coding RNAs (lncRNAs) has important impacts on progression of MM. Circular RNAs (circRNAs) are correlated with malignancy in the modulation of tumor progression. This study aims to investigate the effect of circ_0000190 on regulating the progression of MM.

Method: Microscopic examination via single molecule fluorescent in situ hybridization indicates the location of circ_0000190. qRT-PCR and Western blot were used to evaluate the expression of RNAs and proteins. Potential target of circ_0000190 was searched as miRNA, and examined by luciferase reporter assay. A computational screen was also conducted to search the potential target of miRNA. In vitro cell viability, proliferation, apoptosis assays and flow cytometric were performed to assess the effects of circ_0000190 and its target on MM. Mice model of human MM was established with subcutaneous xenograft tumor, qRT-PCR and western blot were performed to detect the underlying mechanisms of circ_0000190 on MM.

Results: Circ_0000190 was located in the cytoplasm, and down-regulated in both bone marrow tissue and peripheral blood, while the target of circ_0000190, miR-767-5p, was up-regulated, suggesting a negative correlation between them. The binding ability between circ_0000190 and miR-767-5p was confirmed by luciferase reporter assay. Moreover, circ_0000190 inhibited cell viability, proliferation and induced apoptosis of MM thus inhibiting cell progression, which is partially through the negative regulation of miR-767-5p. Mitogen-activated protein kinase 4 (MAPK4) is a direct target of miR-767-5p. In addition, over-expression of miR-767-5p promoted cell progression by directly targeting and regulating MAPK4. The MM model mice with administration of circ_0000190 suppressed tumor growth and progression.

Conclusion: Our results revealed that the ability of circ_0000190 to protect against MM was inherited through repression of miR-767-5p, and miR-767-5p might be a tumor drive through targeting MAPK4. Therefore, a novel role of circ_0000190 on regulating the progression of MM was found, and the clinical application of circRNAs might represent a strategy in MM.

Citing Articles

Circular RNA as Diagnostic and Prognostic Biomarkers in Hematological Malignancies:Systematic Review.

Gao L, Fan J, He J, Fan W, Che X, Wang X Technol Cancer Res Treat. 2024; 23:15330338241285149.

PMID: 39512224 PMC: 11544746. DOI: 10.1177/15330338241285149.


Recent Progress of CircRNAs in Hematological Malignancies.

Cui Y, Wang L, Xu J, Nan H, Yang P, Niu J Int J Med Sci. 2024; 21(13):2544-2561.

PMID: 39439468 PMC: 11492881. DOI: 10.7150/ijms.98156.


Dysregulated Expression Patterns of Circular RNAs in Cancer: Uncovering Molecular Mechanisms and Biomarker Potential.

DeSouza N, Nielsen K, Jarboe T, Carnazza M, Quaranto D, Kopec K Biomolecules. 2024; 14(4).

PMID: 38672402 PMC: 11048371. DOI: 10.3390/biom14040384.


Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R-ISS II patients.

Papatsirou M, Kontos C, Ntanasis-Stathopoulos I, Malandrakis P, Sideris D, Fotiou D Hemasphere. 2024; 8(1):e34.

PMID: 38434522 PMC: 10878196. DOI: 10.1002/hem3.34.


Novel_circ_003686 regulates the osteogenic differentiation of MSCs in patients with myeloma bone disease through miR-142-5p/IGF1 axis.

Qiu L, Ma L, Chen D, Zhang N, Cai J, Zhang Q J Bone Oncol. 2023; 43:100509.

PMID: 38021072 PMC: 10654027. DOI: 10.1016/j.jbo.2023.100509.


References
1.
Harper J, Adams P . Cyclin-dependent kinases. Chem Rev. 2001; 101(8):2511-26. DOI: 10.1021/cr0001030. View

2.
Wang F, OHare M, Park D . Cyclin-dependent kinases and stroke. Expert Opin Ther Targets. 2003; 5(5):557-567. DOI: 10.1517/14728222.5.5.557. View

3.
Nowak N, Gaile D, Conroy J, McQuaid D, Cowell J, Carter R . Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet Cytogenet. 2005; 161(1):36-50. DOI: 10.1016/j.cancergencyto.2005.01.009. View

4.
Coulombe P, Meloche S . Atypical mitogen-activated protein kinases: structure, regulation and functions. Biochim Biophys Acta. 2006; 1773(8):1376-87. DOI: 10.1016/j.bbamcr.2006.11.001. View

5.
Hideshima T, Mitsiades C, Tonon G, Richardson P, Anderson K . Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007; 7(8):585-98. DOI: 10.1038/nrc2189. View